Ikeda, T.; Kawabori, M.; Zheng, Y.; Yamaguchi, S.; Gotoh, S.; Nakahara, Y.; Yoshie, E.; Fujimura, M.
Intranasal Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Hypoxic-Ischemic Brain Injury. Pharmaceutics 2024, 16, 446.
https://doi.org/10.3390/pharmaceutics16040446
AMA Style
Ikeda T, Kawabori M, Zheng Y, Yamaguchi S, Gotoh S, Nakahara Y, Yoshie E, Fujimura M.
Intranasal Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Hypoxic-Ischemic Brain Injury. Pharmaceutics. 2024; 16(4):446.
https://doi.org/10.3390/pharmaceutics16040446
Chicago/Turabian Style
Ikeda, Takuma, Masahito Kawabori, Yuyuan Zheng, Sho Yamaguchi, Shuho Gotoh, Yo Nakahara, Erika Yoshie, and Miki Fujimura.
2024. "Intranasal Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Hypoxic-Ischemic Brain Injury" Pharmaceutics 16, no. 4: 446.
https://doi.org/10.3390/pharmaceutics16040446
APA Style
Ikeda, T., Kawabori, M., Zheng, Y., Yamaguchi, S., Gotoh, S., Nakahara, Y., Yoshie, E., & Fujimura, M.
(2024). Intranasal Administration of Mesenchymal Stem Cell-Derived Exosome Alleviates Hypoxic-Ischemic Brain Injury. Pharmaceutics, 16(4), 446.
https://doi.org/10.3390/pharmaceutics16040446
